Natalizumab for multiple sclerosis: A complicated treatment

The Lancet Neurology

Volumn 10, Issue 8, 2011, Pages 677-678

  Keegan, B Mark ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MEFLOQUINE; NATALIZUMAB; VIRUS ANTIBODY;

BRAIN BIOPSY; CEREBROSPINAL FLUID CULTURE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; DISABILITY; DISEASE CONTROL; DRUG APPROVAL; DRUG EXPOSURE; DRUG INFORMATION; DRUG MEGADOSE; DRUG RECALL; FALSE NEGATIVE RESULT; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; LETTER; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PATIENT MONITORING; PLASMAPHERESIS; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK REDUCTION; SERODIAGNOSIS; TREATMENT DURATION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 79960364322     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70150-8     Document Type: Letter

References (8)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:889-910.
2. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007, 68:1390-1401.
3. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011, 10:745-758.
4. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007, 6:431-444.
5. Khatri B, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009, 72:402-409.
6. Lenhard T, Biller A, Mueller W, Metz I, Schönberger J, Wildemann B Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?. Neurology 2010, 75:831-833.
7. Clifford D, Nath A, Cinque P, et al. Mefloquine treatment in patients with progressive multifocal leukoencephalopathy (PML). Neurology 2011, 76(suppl 4):A28. (abstr P01.023).
8. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010, 68:392-395.